These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 33108366)

  • 1. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
    Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
    PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
    Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
    Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
    Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk factors in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
    Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study.
    Liu HH; Cao YX; Sun D; Jin JL; Guo YL; Wu NQ; Zhu CG; Gao Y; Dong QT; Zhao X; Li S; Zhang Y; Liu G; Li JJ
    Clin Transl Gastroenterol; 2019 Feb; 10(2):e00011. PubMed ID: 30829918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Simon TG; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
    Gut; 2022 Sep; 71(9):1867-1875. PubMed ID: 34489307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
    Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.
    Wu S; Wu F; Ding Y; Hou J; Bi J; Zhang Z
    Sci Rep; 2016 Sep; 6():33386. PubMed ID: 27633274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
    Chinnadurai R; Ritchie J; Green D; Kalra PA
    Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
    Chinnadurai R; Chrysochou C; Kalra PA
    Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure.
    Valbusa F; Agnoletti D; Scala L; Grillo C; Arduini P; Bonapace S; Calabria S; Scaturro G; Mantovani A; Zoppini G; Turcato E; Maggioni AP; Arcaro G; Targher G
    Int J Cardiol; 2018 Aug; 265():162-168. PubMed ID: 29739707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
    Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
    BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
    Zou B; Yeo YH; Jeong D; Park H; Sheen E; Lee DH; Henry L; Garcia G; Ingelsson E; Cheung R; Nguyen MH
    Dig Dis Sci; 2020 May; 65(5):1520-1528. PubMed ID: 31598919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.